Innovative Platform - ‘OptiLinked’ FDCs

Solid tumours require therapies that can penetrate tumours rapidly and completely, whilst clearing from normal tissues quickly. With its revolutionary OptiLinkTM technology platform, Antikor has adopted an altogether more novel approach for ADCs using much smaller antibody fragments (single-chain scFvs) that are relatively easy to discover and can be selected with a high number of surface lysine residues for multiple drug-molecule conjugation via their -NH2 side-chains. Quite counter-intuitively, this provides far higher payloads loadings on a small fragment than have so far been achieved with whole MAbs, without running the risk of product manufacturing or stability problems.


1. Deonarain MP, Yahioglu G. Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy. Expert Opin Drug Discov. 2021 Jun;16(6):613-624. doi: 10.1080/17460441.2021.1858050. Epub 2021 Jan 11. PMID: 33275475.

2. Deonarain MP, Xue Q. Tackling solid tumour therapy with small-format drug conjugates. Antib Ther. 2020 Nov 25;3(4):237-245. doi: 10.1093/abt/tbaa024. PMID: 33928231; PMCID: PMC7990258.

3. Anti-HER2, high-DAR Antibody Fragment Drug Conjugates (FDC) with a Glucuronide-based MMAE linker-payload demonstrates superior efficacy over IgG-based ADCs. Manuscript in preparation for 2024











OptiLinked-FDC platform advantages:-